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Abstract 
As the prevalence of obesity among children has risen, metabolic syndrome, a cluster of 
abnormalities which includes obesity, altered glucose metabolism, hypertension, and 
dyslipidemia, has increasingly become recognized in the pediatric population.  Metabolic 
syndrome has been studied extensively in adults, and there is increasing interest to understand 
the condition in adolescents; however, studies of metabolic syndrome in younger children are 
limited.  The purpose of this study is to examine the prevalence of metabolic syndrome and its 
individual components among children aged 6-10 years.  Demographic, anthropometric, and 
biochemical data were gathered retrospectively from the medical records of 222 obese children 
aged 6-10 years who were seen as new patients in a hospital-based clinic for management of 
obesity and related conditions. The results of this study suggest that the study population is at 
high risk of morbidity; 77.9% of subjects had at least one metabolic abnormality in addition to 
obesity, and 27.9% of subjects in this study had metabolic syndrome.  This study found a high 
risk of elevated systolic blood pressure and elevated fasting insulin in the study population, with 
63.1% of subjects having prehypertension or hypertension and 40.1% of subjects having elevated 
fasting insulin. The results of this study suggest that current recommendations for screening of 
metabolic abnormalities in obese school-age children are not sufficiently aggressive.  Current 
standards of practice do not include assessment for metabolic syndrome components in children 
under the age of 10 years, with the exception of blood pressure.  The prevalence of impaired 
glucose metabolism, insulin resistance, and dyslipidemia, however, is significant in this 
population, and screening for these abnormalities in children under the age of 10 is warranted.   
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Introduction:  The Problem and its Scope 
The prevalence of obesity among children has increased rapidly over the past 30 years.  
In the United States between 1974 and 2004, rates of obesity have risen from 4.0% to 18.8% 
among children aged 6 to11 years (National Center for Health Statistics).  This increase is of 
great public health concern as obese children are at higher risk for a variety of metabolic, 
psychological, orthopedic, respiratory, and cardiovascular conditions (Daniels, 2006).
One condition commonly associated with adult obesity is metabolic syndrome, a cluster 
of abnormalities which includes altered glucose metabolism, hypertension, and dyslipidemia 
(Steinberger, 2003). Metabolic syndrome is associated with increased risk of several chronic 
illnesses.  For example, adults with metabolic syndrome are five times more likely to develop 
type 2 diabetes and three times more likely to develop cardiovascular disease than their 
counterparts who do not have metabolic syndrome (Zimmet et al., 2007).   
As the prevalence of childhood obesity has risen, metabolic syndrome has increasingly 
become recognized in the pediatric population.  The overall prevalence of a metabolic syndrome 
phenotype among U.S. adolescents aged 12-19 years increased from 4.2% in 1988-1992 to 6.4% 
in 1999-2000 in one survey (Duncan, Li, & Zhou, 2004).  In the same survey, the prevalence of 
metabolic syndrome among obese adolescents (BMI ≥ 95th percentile for age) was 32.1%. 
Metabolic syndrome in childhood and adolescence is a strong risk factor for chronic illness in 
these age groups (Calcaterra et al., 2008).  In multiple studies, obese children who had 
components of metabolic syndrome exhibited cardiovascular pathology such as increased carotid 
intima-media thickness and enlarged left ventricular wall thickness (Kapiotis et al., 2006; Chinali 
et al., 2008). 
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Metabolic syndrome has been studied extensively in adults, and there is increasing 
interest to understand this condition in adolescents; however, studies of metabolic syndrome in 
younger children are limited.  If obese adolescents and adults are at risk of developing multiple 
metabolic abnormalities which increase the potential for cardiovascular disease, it seems 
plausible that obese younger children may share the same risk profile.  In fact, development of 
risk factors early in life may result in earlier onset of cardiovascular disease and poorer outcomes 
due to longer duration of exposure (Halpern et al., 2010).  Therefore, it is necessary to explore 
the prevalence and effects of metabolic abnormalities in young obese children.   
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Statement of Purpose 
The purpose of this study is to describe the prevalence of metabolic syndrome and its 
individual components among overweight and obese children aged 6-10 years.  In addition, this 
study will explore how the prevalence of metabolic syndrome, prevalence of individual 
metabolic abnormalities, and number of metabolic abnormalities per individual varies with 
severity of obesity in this population.   
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Review of Literature 
Pediatric Metabolic Syndrome and Adult Morbidity 
Childhood metabolic syndrome tracks into adulthood and is a risk factor for adult 
diseases. In a study by Morrison, Friedman, and Gray-McGuire (2007) which followed 6-19 
year old children over more than 20 years, 68% of subjects with pediatric metabolic syndrome 
had metabolic syndrome as adults.  In another study which followed 9-18 year old children for 
14-27 years, youth with metabolic syndrome had a 2.7-3.4 times higher risk of developing adult 
metabolic syndrome compared to youth without metabolic syndrome (Magnussen et al., 2010).  
Finally, in a study by Chen, Srinivasan, Li, Xu, and Berenson (2005), children with three or more 
metabolic syndrome components in the bottom quartile among study subjects had significantly 
lower prevalence of adult metabolic syndrome than children with less than three risk variables in 
the bottom quartile.   
There are multiple factors which affect the tracking of metabolic syndrome from
childhood to adulthood. The more obese a child is at baseline measurement, the more likely he 
or she is to develop metabolic syndrome later in life (Bao, Srinivasan, Wattigney, & Berenson, 
1994; Whitlock, Williams, Gold, Smith, & Shipman, 2005).  In a 2007 study by Morrison and 
colleagues, for each 10-point increase in age-specific BMI percentile at baseline, the risk of adult 
metabolic syndrome increased by 24%.  Greater increase in BMI over time is also associated 
with greater stability in the metabolic syndrome diagnosis (Bao et al., 1994; Weiss, Shaw, 
Savoye, & Caprio, 2009). In a 2009 study by Weiss and colleagues, all subjects without 
metabolic syndrome at baseline who developed it at follow up had either maintained or increased 
their BMI z-score. Conversely, 84% of subjects who had metabolic syndrome in childhood but 
not at follow up had either decreased or maintained their BMI z-score.
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Tracking of metabolic syndrome from childhood to adulthood is also associated with age 
at baseline and number of cardiometabolic abnormalities in childhood.  The later in childhood a 
young person has metabolic syndrome, the more likely he or she is to maintain the diagnosis as 
an adult (Bao et al., 1994; Whitlock et al., 2005).  In addition, the risk of adult metabolic 
syndrome increases as the number of metabolic syndrome components in youth increases 
(Magnussen et al., 2010; Weiss et al., 2009).   
Childhood metabolic syndrome is associated with adult morbidity.  In one study by 
Morrison, Friedman, Wang, and Gluek (2008), a diagnosis of metabolic syndrome in childhood 
resulted in an 11-fold increase in risk of type 2 diabetes in adulthood.  Diagnosis of pediatric 
metabolic syndrome is also associated with development of cardiovascular disease.  In one study, 
diagnosis of pediatric metabolic syndrome was associated in two-fold higher risk of developing 
an increase in carotid intima-media thickness in adulthood, a sign of atherosclerosis (Magnussen 
et al., 2010). In another study which followed 6-19 year old children over more than 20 years, 
the incidence of cardiovascular disease was 19.4% among adults who had metabolic syndrome as 
children, and only 1.5% among adults without metabolic syndrome as children (Morrison, 
Friedman, & Gray-McGuire, 2007).   
Defining Metabolic Syndrome 
The identification of metabolic abnormalities is extremely important in determining 
cardiovascular risk in children; however, diagnosis of metabolic syndrome is difficult as there is 
currently no consistent, accepted definition for the condition in pediatrics.  In adults, metabolic 
syndrome is typically defined using sets of diagnostic criteria from the National Cholesterol 
Education Program (NCEP) Adult Treatment Panel III (ATP III), the World Health 
Organization, (WHO), or the International Diabetes Foundation (IDF).  While these criteria 
 
 
    
  
Type 2 diabetes, impaired fasting 
glucose, impaired glucose tolerance, 
or insulin resistance.   
 
 
  
 
 
 
    
 
 
  
 
 
 
 
 
  
 
  
 
 
  
  
  
 
 
  
  
  
  
 
 
  
 
  
  
 
  
 
 
 
9 
differ slightly, they all utilize a measure of body fatness, hypertension, dyslipidemia, and glucose 

intolerance (Battista, Murray, & Daniels, 2009).  The following table summarizes the ATP III, 

WHO, and IDF diagnostic criteria for adults. 

Table 1 

Selected diagnostic criteria for metabolic syndrome in adults.   
NCEP ATP III WHO IDF
Waist circumference of
≥ 94 cm for Europid males 
≥ 80 cm for Europid females 
(Other ethnicity-specific waist 
circumferences are available)
≥ 3 of the following: Plus ≥ 2 of the following: Plus ≥ 2 of the following: 
Waist circumference of BMI > 30 kg/m2 
> 102 cm for males and/or
> 88 cm for females Waist-to-hip ratio of 
> 0.9 for males 
> 0.85 for females 
Triglycerides > 150 mg/dL Triglycerides > 150 mg/dL 
and/or
HDL < 35 mg/dL for males 
HDL < 39 mg/dL for females 
Triglycerides ≥ 150 mg/dL 
Or specific treatment for this 
abnormality. 
HDL < 40 mg/dL for males 
HDL < 50 mg/dL for females 
HDL < 40 mg/dL for males 
HDL < 50 mg/dL for females 
Or specific treatment for this 
abnormality.
Systolic BP ≥ 130 mm/Hg 
Diastolic BP ≥ 85 mm/Hg
Systolic BP > 140 mm/Hg 
Diastolic BP > 90 mm/Hg 
Systolic BP ≥ 130 mm/Hg or
Diastolic BP ≥ 85 mm/Hg
Or specific treatment for previously-
diagnosed hypertension.   
Fasting glucose ≥110 mg/dL Fasting glucose ≥100 mg/dL
Or previously-diagnosed type 2 
diabetes. 
Urinary albumin excretion rate ≥ 20
μg/min Or
Albumin: creatinine ratio ≥ 30 mg/g 
(National Cholesterol Education Program, 2001; Alberti & Zimmet, 1998; International Diabetes 
Federation, 2005)
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Criteria for metabolic syndrome in adults have been adapted for use in children by 
utilizing age and sex-specific cutoffs for different metabolic parameters; however, adaptation is 
difficult due to a variety of factors. Because children and adolescents are growing and changing
rapidly, singular cut-points for risk factors such as hypertension cannot be applied across the 
pediatric population. In addition, the physiological insulin resistance of puberty confounds 
measures of glucose intolerance in this population (Steinberger et al., 2009).  Finally, waist 
circumference, which is a key measure of abdominal adiposity in adult criteria, is not commonly 
used in children. Although the United States, Canada, and the United Kingdom have age and 
sex-specific reference values for waist circumference, they have not been endorsed by any 
organization and, as a result, are not routinely used in clinical practice (Zimmet et al., 2007).   
Adaptations of adult criteria for metabolic syndrome in children vary greatly.  In a 2008 
review by Ford and Li, more than 40 different definitions were found in studies of metabolic 
syndrome in children and adolescents.  In 2007, the International Diabetes Federation attempted 
to establish a consensus definition, but it contained several weaknesses, including utilization of 
waist-circumference cutoffs and lack of criteria for children under 10 years of age (Zimmett et 
al., 2007). As a result, the IDF consensus definition is not widely used in clinical practice or in 
research. 
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Table 2 
International Diabetes Federation criteria of at-risk groups and metabolic syndrome in children 
and adolescents.* 
6 to less than 10 years of age 10 to less than 16 years of age 16 years of age and above 
Obesity Waist circumference
≥ 90th percentile for age and
sex 
Metabolic syndrome cannot be
diagnosed, but further 
measurements should be made
of there is a family history of 
obesity-related illness. 
Waist circumference
≥ 90th percentile for age and
sex or adult cut-off if lower 
Waist circumference of
≥ 94 cm for Europid males 
≥ 80 cm for Europid females 
(Other ethnicity-specific waist 
circumferences are available)
Triglycerides Triglycerides ≥ 150 mg/dL Triglycerides ≥ 150 mg/dL 
Or specific treatment for this 
abnormality.
High-Density 
Lipoprotein
(HDL)
HDL < 40 mg/dL HDL < 40 mg/dL for males 
HDL < 50 mg/dL for females 
Or specific treatment for this 
abnormality. 
Blood Pressure Systolic BP ≥ 130 mm/Hg or
Diastolic BP ≥ 85 mm/Hg
Systolic BP ≥ 130 mm/Hg or
Diastolic BP ≥ 85 mm/Hg
Or specific treatment for 
previously-diagnosed
hypertension.
Altered 
Glucose 
Metabolism 
Fasting glucose ≥100 mg/dL
Or previously-diagnosed type
2 diabetes.   
Fasting glucose ≥100 mg/dL
Or previously-diagnosed type
2 diabetes.   
* 	Diagnosis requires presence of abdominal obesity as measured by waist circumference plus at  
least two of the other four factors. 
(Zimmet et al., 2007)
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Table 3 
Pediatric metabolic syndrome definitions in widely-cited studies.   
Study
Cook et al., 
2003 
De Ferranti 
et al., 2004 
Weiss et 
al., 2004 
No. of 
Risk
Factors
≥ 3 
≥ 3 
≥ 3
Obesity
Waist 
circumference  
≥ 90th 
percentile for 
age and sex 
Waist 
circumference 
> 75th 
percentile for 
age and sex 
Body mass 
index z-score 
≥ 2.0
 Blood Pressure Triglycerides 
High-Density 
Lipoprotein
Glucose 
Intolerance
Cruz et al., 
2004 
Ford et al., 
2005 
≥ 3 
≥ 3 
Waist 
circumference  
≥ 90th 
percentile for 
age and sex 
Waist 
circumference  
≥ 90th 
percentile for 
age and sex 
≥ 90th ≥ 110 mg/dL ≤ 40 mg/dL Fasting glucose 
percentile for ≥ 110 mg/dL
age, sex, and 
height
> 90thpercentile ≥ 100 mg/dL < 50 mg/dL Fasting glucose 
for age, sex, ≥ 110 mg/dL
and height
> 95th > 95th < 5th percentile Glucose 140­
percentile for percentile 199 mg/dL 2 h
age, sex, and following 75 g
height glucose load
> 90th ≥ 90th ≤ 10th Glucose 140­
percentile for percentile percentile 199 mg/dL 2 h
age, sex, and following 75 g
height glucose load
≥ 90th ≥ 110 mg/dL ≤ 40 mg/dL Fasting glucose 
percentile for ≥ 110 mg/dL
age, sex, and 
height
While a single, accepted definition would be helpful for clinicians and researchers, it is 
not necessary for the exploration of metabolic syndrome in children.  A recent study by Rinaldi 
and colleagues (2010) observed great agreement among six commonly used diagnostic criteria 
for metabolic syndrome in children.  Regardless of the definition chosen, it is widely accepted 
that multiple metabolic abnormalities place children at heightened cardiovascular risk.  The 
definition chosen for metabolic syndrome is not important as long as these abnormalities are 
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identified and addressed. Therefore, at this time researchers and clinicians should select 
definitions based on the components available in a given situation.   
Measures of Adiposity for Metabolic Syndrome 
An essential element of any study or clinical assessment of metabolic syndrome is a 
measure of body fatness.  However, it is difficult to directly measure body fat in clinical or 
community settings because accurate methods such as dual-energy x-ray absorptiometry 
(DEXA), hydrostatic underwater weighing (hydrodensitometry), and air displacement 
plethysmography are time-consuming and expensive.  As a result, it is often necessary to utilize 
anthropometric measures such as waist circumference and body mass index (BMI) to estimate 
body fatness.  Waist circumference will not be used as a measurement of adiposity in this study 
because it is not routinely collected in the clinic from which subjects will be chosen.  As was 
mentioned above, waist circumference has not been recommended for clinical use by any 
professional organization because comparative standards and high-risk cutoffs have not been 
established (Zimmet et al., 2007). 
In the clinic from which subjects will be selected, BMI is routinely used to assess 
adiposity. BMI is a measure of body weight adjusted for height, defined as weight in kilograms 
divided by the square of height in meters (kg/m2). BMI assessment has many strengths; it is 
easily calculated from weight and height, which are routinely collected for most children.  In 
addition, BMI accurately predicts body fatness (Pietrobelli et al., 1998; Mei et al., 2002).  In a 
study which compared BMI to fat-mass index (kg fat/height2) in children aged 5-18 years, the 
correlation between the two measures was very strong for overweight and obese children 
(r=0.85-0.96) (Freedman et al., 2005).  BMI also correlates well with health risk.  In a study of 
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children aged 9-13 years, BMI greater than the 95th percentile for age was a specific and 
sensitive predictor of the presence of 3 or more metabolic abnormalities (Ice et al., 2009).   
The Expert Committee on the Assessment, Prevention, and Treatment of Child and 
Adolescent Overweight and Obesity recommends use of the Centers for Disease Control and 
Prevention (CDC) BMI-for-age charts to screen for excess adiposity in children and adolescents 
(Barlow &The Expert Committee, 2007).  The CDC, American Academy of Pediatrics, and 
Institutes of Medicine all recommend using the 85th and 95th percentiles as cutoffs for increased 
health risks due to excess body weight. BMI greater than or equal to the 85th percentile but less 
than the 95th percentile is termed “overweight”, while BMI greater than or equal to the 95th 
percentile is termed “obese” (Barlow & The Expert Committee, 2007).   
While BMI is a very useful tool, the CDC’s BMI growth curve and its cutoff points it 
have several disadvantages. For example, children between the 85th and 95th percentile may 
actually have a large amount of lean mass as opposed to fat mass, so interpretation of BMI for 
children who fall into this range must be done with care.  In addition, the curve does not 
sufficiently describe risk among obese children.  For example, there is a large difference in 
adiposity and risk of health problems between a child weighing 200 pounds and another 
weighing 300 pounds, but they both fall into the same risk category (BMI ≥ 95th percentile) 
(Barlow & The Expert Committee, 2007).  As a result, the Expert Committee (2007) has 
proposed recognition of a third cutoff point, BMI ≥ 99thpercentile for age, which will be 
indicative of severe obesity. 
Among individual children between the 5th and 95th percentiles for age, changes in BMI 
percentile can be used to monitor changes in relative adiposity.  Percentiles are not useful, 
however, for children above the 95th percentile, because accurate percentile cutoffs are not 
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available. In addition, raw BMI (BMI not interpreted using a growth chart) is not useful for 
individual children or groups of children as a result of differences in expected BMI due to age-
related growth (Woo, 2009).  To remedy these particular problems, standardized measures such 
as BMI z-scores were developed. BMI z-scores can be used for groups of children and 
individuals with BMI percentiles above the 95th to describe degree of adiposity and changes in 
adiposity. In a study of children aged 2-5 years, BMI z-score was better than raw BMI or BMI 
percentile in assessing adiposity on a single occasion (Cole, 2005).  In another study, which 
compared raw BMI and BMI z-score to measures of body fat using bioelectrical impedance, 
BMI z-score predicted changes in adiposity more accurately than raw BMI (Hunt, Ford, Sabin, 
Crowne, & Shield, 2007). 
Like raw BMI and BMI percentiles, BMI z-scores have several weaknesses.  BMI z-
scores are difficult to calculate, interpret, and explain to families, particularly when they have 
limited knowledge of statistics.  In addition, a 2009 paper by Woo suggests that BMI z-scores 
may not accurately describe changes in weight status among children and adolescents with a 
BMI greater than the 97th percentile for age.  The statistical techniques used to correct for 
skewed raw BMI values in the 2000 CDC growth charts introduce systematic bias among z-
scores in the upper tail of the distribution.  As a result of this bias, the relationship between BMI 
and BMI z-score differs with age, sex, and BMI.  Most notably, a stable high BMI in 
adolescence results in increasing BMI z-scores for boys, and decreasing BMI z-scores for girls.  
Woo (2009) suggests that another method may be needed to accurately describe changes in 
adiposity among the severely obese. 
An alternative to BMI z-scores which is also useful for groups of children and individuals 
with BMI greater than the 95th percentile for age is relative BMI (rBMI).  RBMI is calculated by 
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dividing the subject’s actual BMI by the BMI at the 50th percentile for each subject’s age and 
gender using data from the appropriate CDC BMI chart.  Essentially, rBMI is a percentage of an 
“ideal” or “standard” body weight.  While rBMI is not widely used in the literature to describe 
the severity of overweight, it has several advantages over other methods.  RBMI is a simple 
calculation that can be easily explained to parents and caregivers.  In addition, it accurately 
describes relative adiposity. A study by Cowan, Velasquez, Neira, Villegas-Barreto, and 
Tylavsky (2006) found that rBMI correlates with measures of body fat by dual energy x-ray 
absorptiometry in children across ages, genders, and races.  
Etiology 
There is much debate regarding the etiology of metabolic syndrome because several 
conditions, including obesity, insulin resistance, and inflammation, have been implicated in its 
development (Steinberger et al., 2009).  It is likely that metabolic syndrome is a result of 
complex interactions among these conditions as well as other factors such as heredity and 
lifestyle, as illustrated in Figure 1.   
Genetic and Lifestyle Factors 
Obesity Insulin 
Resistance 
Inflammation 
Metabolic 
Syndrome 
Cardiovascular Disease and Type 2 Diabetes 
Figure 1. Complex etiology of metabolic syndrome. 
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While metabolic syndrome is modulated by many factors, strong evidence supports 
obesity as the predominant correlate of cardiometabolic risk (Goodman, Dolan, Morrison, & 
Daniels, 2005). Metabolic syndrome is extremely rare in normal weight children, but quite 
prevalent in those with excess body fat. In a study of adolescents aged 12-19 years selected from
the National Health and Nutrition Examination Survey (NHANES) 1999-2000, less than 1% of 
normal weight subjects met the age-modified ATP III criteria for metabolic syndrome, while 
32.1% of obese subjects met the criteria (Duncan et al., 2004).   
Within the overweight and obese population, prevalence of metabolic syndrome rises 
with increasing severity of obesity. In a Turkish study which examined metabolic syndrome in 
obese children aged 2-19 years, body mass index (BMI) was the most important determinant of
metabolic syndrome, with a one point increase in BMI z-score doubling the prevalence of the 
condition (Sen, Kandemir, Alikasifoglu, Gonc, & Ozon, 2008).  A similar study by Weiss and 
colleagues (2004) which included subjects aged 4-20 years found significant increases in the 
prevalence of metabolic syndrome with each half-unit increase in BMI.  While metabolic 
syndrome was absent in normal weight and overweight children, 38.7% of moderately obese 
subjects (defined as BMI z-score of 2.0-2.5) and 49.7% of severely obese subjects (BMI z-score 
greater than 2.5) met the criteria for metabolic syndrome.   
Just as prevalence of metabolic syndrome is higher in obese children than in normal 
weight children, the prevalence of each individual abnormality associated with the syndrome is 
higher in obese children. In one study, prevalence of cardiometabolic risk factors including high 
systolic blood pressure, low HDL cholesterol, elevated triglycerides, and high insulin levels were 
all significantly higher among overweight and obese subjects than among normal weight subjects 
(Lambert et al., 2008).  Similarly, prevalence of each abnormality rises with increasing severity 
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of obesity. In the 2004 study by Weiss and colleagues discussed above, glucose, insulin, 
triglycerides, blood pressure, glucose tolerance, and HDL all worsened with increasing obesity, 
independently of age, sex, and pubertal status.   
Finally, the number of metabolic abnormalities per individual is increased among obese 
children, and rises with increasing severity of obesity.  In Lambert and colleagues’ 2008 study, 
the number of components of the metabolic syndrome increased significantly between normal 
weight and overweight children, and between overweight and obese children.  In addition, obese 
boys were 15 times more likely and obese girls were 18 times more likely to have two or more 
metabolic syndrome components than their normal weight counterparts.  In another study, no 
normal weight or overweight subjects had 3 or more metabolic abnormalities, while 12.0% of 
moderately obese subjects and 31.1% of severely obese subjects had 3 or more abnormalities 
(Calcaterra et al., 2008).   
The mechanism by which obesity contributes to development of metabolic syndrome is 
primarily due to its promotion of insulin resistance and inflammation.  Insulin resistance is a 
state in which usual concentrations of insulin do not adequately stimulate utilization of glucose 
by the liver and peripheral tissues (Matthaei, Stumvoll, Kellerer, & Haring, 2000; Weiss & 
Kaufman, 2008).  Insulin resistance is relatively rare in the overall pediatric population, with a 
prevalence of about 4% (Weiss et al., 2004).  It is quite common, however, among obese 
children and adolescents, with a prevalence estimated at 50% or above (Weiss et al., 2004).  In a 
2002 study examining the relationship between adiposity and insulin resistance, body fat 
accounted for 55% of the variance in insulin sensitivity after adjusting for age, gender, race, and 
pubertal stage (Caprio, 2002). In another study by Velasquez-Meiyer, Cowan, Neira, and 
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Tylavsky (2008), two different indices of insulin sensitivity decreased significantly as the 
severity of overweight increased (p<0.01).   
Excess body fat plays an important role in the development of insulin resistance because 
adipose tissue releases metabolites, hormones, and cytokines that disrupt insulin action in the 
body (Chiarelli & Marcovecchio, 2008).  For example, adipose tissue produces the inflammatory 
cytokines interleukin-6 (IL-6), interleukin-1 (IL-1), and tumor necrosis factor-α (TNF- α), which 
disrupt insulin action and contribute to the pathogenesis of insulin resistance (Matsuzawa, 2005).  
Data from animal studies suggest that increased levels of resistin, another molecule produced by 
adipose tissue, impairs insulin sensitivity (Matsuzawa, 2005).  Conversely, another cytokine 
called adiponectin increases insulin sensitivity and decreases the likelihood of insulin resistance.  
Adiponectin levels are lower in children and adolescents with greater amounts of body fat, 
thereby increasing the risk of insulin resistance in this population (Weiss et al., 2004).   
In addition to the amount of body fat, distribution of body fat and ectopic fat deposition is 
implicated in the pathogenesis of insulin resistance.  In a study of obese adolescent females, 
amount of visceral fat was directly correlated with insulin resistance, while there was no 
significant relationship between insulin resistance and abdominal subcutaneous fat (Caprio et al.,
1995). Ectopic fat deposition in the muscle tissue is also associated with insulin resistance due 
to decreased glucose uptake in the muscle.  In several studies, intramyocellular lipid 
accumulation was significantly greater in obese children with insulin resistance than in obese 
children with normal insulin sensitivity (Chiarelli & Marcovecchio, 2008).  Finally, 
accumulation of fat in the liver may cause insulin resistance by interfering with the ability of 
insulin to suppress hepatic glucose production (Weiss & Kaufman, 2008). 
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Insulin resistance contributes too many of the abnormalities associated with metabolic 
syndrome.  Insulin resistance in the liver results in lipogenesis, contributing to dyslipidemia.  
Over time, individuals with insulin resistance develop chronic hyperinsulinemia due to excess 
insulin secretion and/or reduced insulin clearance.  If the pancreas can compensate for the insulin 
resistance, blood sugar levels remain normal; if the pancreas cannot compensate, impaired 
glucose tolerance and type 2 diabetes develop.  There is also some evidence that 
hyperinsulinemia independently contributes to development of obesity, hypertension, and other 
cardiovascular risk factors among children (Steinberger et al., 2009). 
Effects of Gender, Race, and Other Factors
In adults, development of metabolic syndrome is associated with a number of factors 
besides obesity and insulin resistance, including older age, smoking, decreased household 
income, and Mexican-American ethnicity (Park et al., 2003).  Similarly, age, gender, 
race/ethnicity, and family history influence the development of metabolic syndrome in children.   
The prevalence of metabolic syndrome in adolescent males is significantly higher than in 
adolescent females.  In studies which examined NHANES data for adolescents aged 12-19 years, 
prevalence of metabolic syndrome among males was 6.1-9.1%, while prevalence in females was 
only 2.1-3.7% (Cook, Weitzman, Auinger, Nguyen, & Dietz, 2003; Duncan et al., 2004).  In 
younger children, however, there does not appear to be a gender difference.  Multiple studies 
which examined children under the age of 10 found no significant difference in prevalence of 
metabolic syndrome between boys and girls (Calcaterra et al., 2008; Pedrosa et al., 2010; Rinaldi 
et al., 2010). 
There also appear to be gender differences in which components of the metabolic 
syndrome are present.  In a 2010 study by Pedrosa and colleagues which examined metabolic 
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syndrome in obese children aged 7-10 years, hypertension, low HDL, and elevated triglycerides 
were more common in girls, while boys had a significantly higher waist circumference than girls.  
In a similar study by Lambert and colleagues (2008) which examined children aged 9, 13, and 16 
years, girls had significantly more unfavorable outcomes with regards to total cholesterol, low-
density lipoprotein (LDL), HDL, triglycerides, and insulin resistance.  Boys, in contrast, had a 
higher prevalence of impaired fasting glucose.   
Racial and ethnic differences in prevalence of metabolic syndrome among children and 
adolescents are apparent, with prevalence being highest among Hispanics, second-highest among 
non-Hispanic whites, and lowest among non-Hispanic blacks (Cook et al., 2003; DeFerranti et 
al., 2004). There are differences in the components of metabolic syndrome which tend to appear 
in individuals of different racial and ethnic groups.  Obesity and insulin resistance tend to be 
more common in Hispanics and non-Hispanic blacks, and hypertension is most common among 
black individuals. In contrast, blacks generally have more favorable triglycerides and HDL.  
These racial and ethnic differences are not well-understood; it is difficult to tell if one 
racial/ethnic group is truly at higher risk, or if there are different risk thresholds for different 
groups (Steinberger et al., 2009). 
Older children and adolescents are at higher risk for metabolic syndrome than younger 
children. In a 2008 study by Sen, Kandemir, Alikasifoglu, Gonc, and Ozon which examined 
children and adolescents aged 2-19 years, subjects with metabolic syndrome were significantly 
older than those without metabolic syndrome.  In another study by Lambert and colleagues 
(2008) which examined children aged 9, 13, and 16 years, there was an increase in number of 
metabolic abnormalities with age.  Most notably, 16 year old boys were 10 times more likely, 
and 13 year old boys were 4 times more likely to have 2 or more unfavorable cardiometabolic 
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characteristics than their 9 year old counterparts.  Interestingly, this difference in prevalence with 
age does not appear to be associated with pubertal stage, as studies examining children between 
2 and 19 years did not find any difference in prevalence of metabolic syndrome among children 
of different Tanner stages (Cook et al., 2003; Rinaldi et al., 2010; Sen et al., 2008).   
The evidence regarding associations between parental health history and pediatric 
metabolic syndrome is mixed.  Several studies found no association between parental history of 
type 2 diabetes or myocardial infarction and presence of pediatric metabolic syndrome (Cook et 
al., 2003; Sen et al., 2008). Data from the Bogalusa Heart Study, however, showed that 
offspring of parents with early coronary artery disease are more likely to be overweight as 
children and to develop an unfavorable cardiovascular risk profile in early adulthood (Bao et al., 
1997). 
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Methods and Procedures 
Study Population 
Subjects for this study were 222 obese children aged 6-10 years who were seen as new 
patients in the Lipid Clinic at the Children’s Medical Center of Dayton in 2008-2010 for 
management of obesity and related conditions.  Overall, 479 patients met the age and weight 
parameters described above; 257 of these patients were excluded from this study because they 
had missing information on any of the following study measures: five hour oral glucose tolerance 
test, lipid panel, and blood pressure readings. 
Data Collection and Measurement Techniques 
This study protocol was reviewed and approved for appropriate treatment of human 
subjects by the Children’s Medical Center of Dayton’s Institutional Review Board.  All data for 
this study were gathered retrospectively from electronic medical records.  Data gathered included 
age, race/ethnicity, height, weight, and blood pressure from patient’s initial clinic visit, as well as 
results of oral glucose tolerance testing (OGTT), fasting total cholesterol, fasting triglycerides, 
and high-density lipoprotein cholesterol, which were typically drawn within 14 days following 
the initial clinic visit.   
Measures of Adiposity
Height and weight data were collected at each patient’s initial visit to the Lipid Clinic by 
a registered nurse or trained medical office assistant.  Height was measured in meters with 
patient in bare feet or socks using a ProScale model 150 digital stadiometer (Accurate 
Technology Inc., Fletcher, NC, USA).  Weight was measured in a hospital gown to the nearest 
0.1 kilogram on a Detecto Model 6550 folding portable wheelchair scale with Detecto model 
758C digital weight indicator (Cardinal Scale Manufacturing Co., Webb City, Missouri, USA).   
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Body mass index was calculated by dividing the weight of the subject by the height 
squared (kg/m2) (Table 1). BMI percentile was then determined using the Centers for Disease 
Control (CDC) BMI charts for age and gender (National Center for Health Statistics, 2002).  
Overweight was defined as 85th percentile ≤ BMI < 95th percentile, and obesity was defined as 
BMI ≥ 95th percentile as recommended by the Expert Committee on the Assessment, Prevention, 
and Treatment of Child and Adolescent Overweight and Obesity (Barlow & The Expert 
Committee, 2007).   
In addition to classification into overweight and obese categories, degree of excess 
weight was described using BMI percentiles and relative BMI (rBMI).  Relative BMI is 
calculated by dividing the subject’s actual BMI by the BMI at the 50th percentile for each 
subject’s age and gender using data from the appropriate CDC BMI chart (Table 4).  For 
analyses, the population was stratified into rBMI tertiles.   
Table 4 
Relative Body Mass Index Formulas 
Measurement Formula 
Body Mass Index 
Body Mass Index at 50th 
Percentile (Females) 
Body Mass Index at 50th 
Percentile (Males) 
Relative Body Mass Index 
Body weight (kg) / height2 (m2) 
-0.0041x3 + 0.1529x2 – 1.2696x + 18.249 

(x = age in years, rounded to the nearest 0.01 year) 

-0.0028x3 + 0.1253x2 – 1.152x + 18.41 

(x = age in years, rounded to the nearest 0.01 year) 

(Body Mass Index / Body Mass Index at 50th Percentile)
 
(National Center for Health Statistics, 2002)
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Measures of Blood Pressure 
Blood pressure data were collected at each patient’s initial visit to the Lipid Clinic by a 
registered nurse or trained medical office assistant.  If more than one blood pressure was 
collected during the initial visit, the lowest blood pressure was used for this study.  Blood 
pressures were measured with the patient seated using a GE Dinamap Pro 100V2 blood pressure 
monitor (GE Healthcare, Milwaukee, WI, USA) with appropriately sized cuff, and were
interpreted using the age, sex, and height-specific National Heart, Lung, and Blood Institute 
(NHLBI) blood pressure tables for children and adolescents (National Heart, Lung, and Blood 
Institute [NHLBI], 2005). 
For the purposes of this study, prehypertension was defined as a systolic or diastolic 
blood pressure greater than or equal to the 90th percentile, but less than the 95th percentile. In 
addition, patients with systolic blood pressure below the 90th percentile but greater than or equal 
to 120 mmHg and/or diastolic blood pressure below the 90th percentile but greater than or equal 
to 80 mmHg were considered to be pre-hypertensive.  Stage 1 hypertension was defined as a 
systolic blood pressure and/or diastolic blood pressure greater than or equal to the 95th percentile 
for sex, age, and height, but less than the 99th percentile cutoff plus 5 mmHg. Finally, stage 2 
hypertension was defined as systolic and/or diastolic blood pressure greater than the 99th 
percentile cutoff plus 5 mmHg. These definitions are consistent with the NHLBI’s definitions, 
except the NHLBI recommends using the average of three blood pressures which are obtained on 
different occasions (NHLBI, 2005).   
Measures of Glucose Tolerance and Insulin Resistance 
Blood glucose and insulin data were collected at the Children’s Medical Center of 
Dayton’s short-stay unit within two weeks of the patient’s initial clinic visit.  Glucose tolerance 
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was measured following a 12 hour fast using the World Health Organization’s oral glucose 
tolerance test protocol. In this protocol, plasma glucose and insulin are monitored in the fasting 
state and at one hour intervals following oral administration of anhydrous glucose dissolved in 
water. Glucose dosing is 1 gram per kilogram of body weight, with a maximum dose of 75 
grams (World Health Organization/International Diabetes Federation, 2006).  For this study, the 
American Diabetes Association’s definitions for impaired fasting glucose, impaired glucose 
tolerance, and type 2 diabetes were used. Impaired fasting glucose was defined as fasting 
glucose greater than or equal to 100 mg/dL; impaired glucose tolerance was defined as a two 
hour postload glucose of 140 to 199 mg/dL, and type 2 diabetes was defined as a two hour 
postload glucose of greater than or equal to 200 mg/dL (American Diabetes Association, 2005).   
Elevated fasting insulin was defined as fasting insulin greater than or equal to 17 u 
IU/mL.  Degree of insulin resistance was calculated from fasting plasma glucose and insulin 
levels using the fasting glucose-to-insulin ratio (FGIR) and homeostatic model assessment of 
insulin resistance (HOMA-IR).  FGIR is calculated by dividing fasting glucose in mg/dL by 
fasting insulin in u IU/mL, while HOMA-IR is calculated by multiplying glucose in mg/dL by 
insulin in uIU/mL, then dividing the product by 405.  FGIR is inversely related to insulin 
resistance, with FGIR decreasing as insulin resistance increases. Conversely, HOMA-IR 
increases as insulin resistance increases (Conwell, Trost, Brown, & Batch, 2004). 
Measures of Serum Lipids 
Blood lipid data were collected at the Children’s Medical Center of Dayton’s short-stay 
unit following a 12 hour fast. This lipid panel was drawn within two weeks of the patient’s 
initial clinic visit. For this study, the American Heart Association’s guidelines for identification 
of children and adolescents at high risk for cardiovascular disease was used; high-density 
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lipoprotein below 35 mg/dL or fasting triglycerides greater than or equal to 150 mg/dL were 
considered abnormal (Kavey et al., 2003).   
Metabolic Syndrome 
For this study, metabolic syndrome was defined as BMI greater than or equal to the 85th 
percentile, plus two or more of the following factors: 
 HDL less than 35 mg/dL 
 Triglycerides greater than 150 mg/dL 
 2 hour blood glucose on oral glucose tolerance test greater than or equal to 140 
mg/dL 
 Abnormal blood pressure (Please see definitions of pre-hypertension and 
hypertension, above.) 
Data Analysis 
From the data described above, a variety of analyses were performed.  Mean values for 
age, weight, height, BMI, BMI percentile, rBMI, systolic blood pressure, diastolic blood 
pressure, fasting glucose, two hour glucose, HDL, and total cholesterol were calculated for the 
entire group and for each rBMI tertile.  Additionally, means were calculated for the entire group 
and each rBMI tertile with the population separated by sex.  Two-sample t-tests were used to test 
for significant differences in means between the sexes, and single-factor ANOVA analyses were 
performed to test for significant differences in means amongrBMItertiles.   
Median values for fasting insulin, FGIR, HOMA-IR, and triglycerides were calculated for 
the entire group and for each rBMI tertile.  Additionally, medians were calculated for the entire 
group and each rBMI tertile with the population separated by sex.  Mann-Whitney tests were 
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used to test for significant differences in medians between the sexes, Kruskal-Wallis tests were 
performed to test for significant differences in medians among rBMI tertiles.   
Racial distribution was examined for the population as a whole and for each rBMI tertile.  
Additionally, the distribution was examined for the entire group and each rBMI tertile with the 
population separated by sex. Chi-square analysis was used to test for significant differences in 
race distribution between males and females and among rBMI subgroups.  Proportions of 
children with abnormal metabolic parameters were examined for the population as a whole and 
for each rBMI tertile.  Chi-square analysis was used to test for significant differences in 
prevalence of abnormalities between males and females, and among rBMI subgroups.  Finally, 
the number of metabolic syndrome components and prevalence of metabolic syndrome was 
calculated for the entire group and for each rBMI tertile.  Chi-square analysis was used to test for 
significant differences between groups. 
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Results
Demographics and Metabolic Characteristics of the Study Population 
Table 5 
Demographics and Metabolic Characteristics of Overall Sample, and by Sex 
Characteristics 
Overall 
N=222 
Mean ± sd, Median 
(IQR) or n (%) 
Males 
N=88 
Mean ± sd, Median 
(IQR) or n (%) 
Females 
N=134 
Mean ± sd, Median 
(IQR) or n (%)
p-value 
Age (y) 9.27 ± 1.33 9.32 ± 1.37 9.24 ± 1.31 0.325†
Race 
White 
Black
Others 
136 (61.3%) 
62 (27.9%) 
24 (10.8%) 
62 (70.4%) 
21 (23.9%) 
5 (5.7%) 
74 (55.2%) 
41 (30.6%) 
19 (14.2%) 
0.040‡
Weight (kg) 62.41 ± 15.06 62.74 ± 13.43 62.18 ± 16.08 0.389†
Height (m)  1.43 ± 0.10 1.42 ± 0.09 1.43 ± 0.11 0.119†
Measures of adiposity 
BMI (kg/m2) 30.35 ± 5.12 31.09 ± 5.37 29.86 ± 4.90 0.044†
BMI percentile 98.99 ± 1.20 99.22 ± 0.65 98.83 ± 1.43 0.001†
Relative BMI 1.85 ± 0.30 1.90 ± 0.33 1.82 ± 0.28 0.032†
Measures of blood pressure
SBP (mmHg) 120.47 ± 10.42 120.03 ± 10.69 120.75 ± 10.28 0.309†
DBP (mmHg) 67.17 ± 6.57 67.08 ± 7.17 67.22 ± 6.17 0.439†
Measures of glucose tolerance / insulin resistance 
F GLU (mg/dL) 92.58 ± 7.16 94.27 ± 7.67 91.46 ± 6.59 0.003†
F INS (u IU/mL ) 14.90 (9.35) 12.85 (8.00) 17.00 (10.65) 0.001§
2H GLU (mg/dL) 119.99 ± 23.75 120.67 ± 24.63 119.54 ± 23.24 0.366†
FGIR 6.21 (4.49) 7.10 (4.66) 5.40 (3.46) <0.0001§
HOMA-IR 3.36 (2.18) 2.91 (2.03) 3.88 (2.27) 0.004§
Measures of serum lipids 
TG (mg/dL) 90.50 (71.5) 85.00 (63.25) 92.00 (76.75) 0.221§
HDL (mg/dL) 41.72 ± 9.39 43.48 ± 10.27 40.56 ± 8.61 0.493†
CHOL (mg/dL) 164.66 ± 32.70 169.18 ± 34.10 161.69 ± 31.52 0.389†
Two sample t-tests or Mann-Whitney tests were conducted to test sex differences in continuous variables (e.g., age). 
Chi-square test was used to examine sex difference in categorical variable (e.g., race). 
† 2-sample t-test assuming unequal variances 
‡ Chi-square test
§ Mann-Whitney test
Demographic Characteristics 
A total of 222 subjects were included in this study, comprising of 39.6% males and 
60.4% females.  The mean ± sd age of participants was 9.27 ± 1.33 years; there was no 
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significant difference between the mean age of males and females.  Self-described race was 
grouped into three categories: black, white, and others.  Overall, 61.3% of subjects were white, 
27.9% were black, and 10.8% were of another race category and were designated as others, or 
declined to provide this information.  Notably, there was a significant difference in the racial 
distribution of male and female participants on Chi-square analysis (p=0.04).  While 70.4% of 
male participants were white, only 55.2% of female participants were white (Table 5). 
Weight and Height 
Mean ± sd weight of participants was 62.41 ± 15.06 kilograms, and mean height of 
participants was 1.43 ± 0.10 meters; there were no significant differences in mean weight or 
height between male and female participants.  However, mean BMI of male participants was 
significantly higher than the mean BMI of female participants.  In addition, rBMI, which adjusts 
for age and sex, remained significantly higher in males than in females (p=0.032) (Table 5).    
Blood Pressure 
Table 6 
Blood Pressure Profiles in Overall Sample, and by Sex  
Blood Pressure 
Category 
Overall 
N=222 
n (%) 
Males
N=88 
n (%) 
Females 
N=134 
n (%)
p-value† 
Normotensive 
Pre HTN 
Stage 1 HTN 
Stage 2 HTN 
82 (36.9%) 
29 (13.1%) 
87 (39.2%) 
24 (10.8%) 
35 (39.8%) 
9 (10.2%) 
34 (38.6%) 
10 (11.4%) 
47 (35.1%) 
20 (14.9%) 
53 (39.6%) 
14 (10.4%) 
0.737 
† Chi-square test
Mean systolic blood pressure of the study population was 120.47 ± 10.42 mmHg, and 
mean diastolic blood pressure was 67.17 ± 6.57 mmHg (Table 5).  There were no significant 
differences in systolic or diastolic blood pressure between males and females.  When age, height, 
and sex-specific cutoffs for hypertension were applied, only 36.9% of subjects were 
normotensive (Table 6).  Overall, 13.1% of subjects had blood pressure categorized as pre­
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hypertension, 39.2% had blood pressure categorized as stage 1 hypertension, and 10.8% had 
blood pressure categorized as stage 2 hypertension.  There was no significant difference between 
males and females with regards to blood pressure categorization.   
Table 7 
Metabolic Abnormalities in Overall Sample, and by Sex  
Characteristics 
Overall 
N=222 
n (%) 
Males
N=88 
n (%) 
Females 
N=134 
n (%)
p-value† 
F GLU ≥ 100 mg/dL 27 (12.2%) 17 (19.3%) 10 (7.5%) 0.008 
F INS ≥ 17 u IU/mL 89 (40.1%) 22 (25.0%) 67 (50.0%) <0.001 
Impaired GTT:  
140-199 mg/dl @ 2h 
26 (11.7%) 12 (13.6%) 14 (10.4%) 0.303 
Type 2 DM: 
≥ 200 mg/dl @ 2 h 
3 (1.4%) 1 (1.1%) 2 (1.5%) 0.654 
HDL < 35 mg/dL 44 (19.8%) 13 (14.8%) 31 (23.1%) 0.086 
TG >150 mg/dL 41 (18.5%) 14 (15.9%) 27 (20.1%) 0.270 
† Chi-square test
Figure 2. Metabolic Abnormalities in Overall Sample, and by Sex 
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Glucose levels
Average fasting glucose of the study population was 92.58 ± 7.16 mg/dL (Table 5).  Male 
subjects had significantly higher mean fasting glucose than female subjects, with a mean level of 
94.27 ± 7.67 mg/dL for males, and 91.46 ± 6.59 mg/dL for females (p=0.003).  Overall, 12.2% 
of subjects had impaired fasting glucose (fasting glucose of greater than or equal to 100 mg/dL) 
(Table 7). There was a significant sex difference between the proportion of individuals who had 
impaired fasting glucose; noted in 19.3% of males versus 7.5% of females (p=0.008).  In 
contrast, there was no significant difference in two hour glucose during glucose tolerance test 
between males and females.  When two hour glucose levels were considered in light of the 
American Diabetes Association’s cutoffs, 11.7% of subjects had impaired glucose tolerance, 
defined as 2 hour blood glucose between 140 and 199, and 1.4% had type 2 diabetes, defined as 
a 2 hour blood glucose of 200 and above. There were no significant differences in prevalence of 
impaired glucose tolerance and type 2 diabetes between males and females (Table 7).
Fasting Insulin and Insulin Sensitivity Indices
The median (IQR) fasting insulin level among all study participants was 14.90 (9.35) u 
IU/ml (Table 5).  There was a significant difference in insulin levels between males and females, 
with males having a median level of 12.85 (8.00) u IU/ml, and females having a median level of 
17.00 (10.65) uIU/mL (p=0.001) (Table 5).  Similarly, 50.0% of females had abnormal fasting 
insulin levels of 17 u IU/mL or greater, while only 25.0% of males had abnormal levels; this 
difference was highly significant (p<0.001). Overall, 40.1% of subjects had abnormal fasting 
insulin levels of 17 u IU/mL or greater. As is to be expected considering differences in insulin 
levels, females were significantly more insulin resistant than males on fasting FGIR and HOMA­
IR (Table 5). 
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Serum Lipids
The median fasting triglyceride level in the study population was 90.50 mg/dL (Table 5), 
and 18.5% of subjects had abnormal triglyceride levels i.e., greater than 150 mg/dL (Table 7).  
There were no significant differences between males and females with regards to median 
triglyceride levels or proportion of individuals with abnormal triglyceride levels.  The mean 
fasting HDL level in the study population was 41.72 ± 9.39 mg/dL (Table 5), and 19.8% of 
subjects had abnormal HDL levels of less than 35 mg/dL (Table 7). As with triglycerides, there 
were no significant differences in mean HDL levels or proportion of individuals with abnormal 
HDL levels between males and females.  Finally, the mean ± sd total cholesterol level among 
study participants was 164.66 ± 32.70 mg/dl; there was no significant difference in mean 
cholesterol levels between male and female participants (Table 5).     
Metabolic Syndrome 
Table 8 
Distribution of Metabolic Syndrome Components in Overall Sample, and by Sex 
Number of 
Components† 
Overall 
N=222 
n (%)
Males 
N=88 
n (%)
Females 
N=134 
n (%)
p-value‡
1 49 (22.1%) 20 (22.7%) 29 (21.6%) 
0.469 
2 111 (50.0%) 48 (54.5%) 63 (47.0%) 
3 46 (20.7%) 15 (17.0%) 31 (23.1%) 
4 13 (5.9%) 5 (5.7%) 8 (6.0%) 
5 3 (1.3%) 0 (0.0%) 3 (2.2%) 
†Components of metabolic syndrome include BMI≥85th percentile, HDL<35, TG>150, 2H glu≥140, and 
prehypertension/hypertension
‡Chi-square test
Note: Everyone is qualified for at least one abnormality based on BMI criteria for inclusion in the study. 
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Figure 3. Distribution of Metabolic Syndrome Components in Overall Sample, and by Sex 
Figure 4.  Prevalence of Metabolic Syndrome in Overall Sample, and by Sex
† Metabolic syndrome is defined as BMI≥85th percentile plus 2 or more of the following variables:  1) HDL<35, 2) 

TG>150, 3) 2H glu≥140, and 4) prehypertension/hypertension

‡Chi-square test
 
Note: Everyone is qualified for at least one abnormality based on BMI criteria. 
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Each subject had at least one metabolic syndrome component because BMI greater than 
or equal to the 85th percentile was one of the inclusion criteria for the study. Only 22.1% of 
subjects had no abnormalities other than overweight or obesity, 50.0% had one additional 
abnormality, 20.7% had two additional abnormalities, 5.9% had three additional abnormalities, 
and 1.3% had every component of the metabolic syndrome (Table 8).  There was no significant 
difference in number of abnormalities between males and females (Table 8).  Metabolic 
abnormalities were clustered into the metabolic syndrome, defined as BMI greater than or equal 
to the 85th percentile, plus two or more of the following variables:  HDL less than 35 mg/dL, 
triglycerides greater than 150 mg/dL, two hour glucose of 140 mg/dLor greater, and 
prehypertension/hypertension. Using this definition, 27.9% of study subjects had metabolic 
syndrome; there was no significant difference in the proportion of males versus females with the 
syndrome (Figure 4).   
Demographics and Metabolic Characteristics by Relative BMI 
Study subjects were divided into relative BMI tertiles in order to stratify them by degree 
of obesity. Subjects in the lowest tertile (tertile one) had relative BMIs greater than 1.24 but less 
than 1.70, subjects in the middle tertile (tertile two) had relative BMIs of 1.70 to less than 1.93, 
and subjects in the highest tertile (tertile three) had relative BMIs of 1.93 to 3.15.   
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Table 9 
Demographics and Metabolic Characteristics of Overall Sample by rBMI Category 
Characteristics
rBMITertile 1 
N=73 
Mean ± sd, Median 
(IQR) or n (%)
rBMITertile 2 
N=71 
Mean ± sd, Median 
(IQR) or n (%)
rBMITertile 3 
N=78 
Mean ± sd, Median 
(IQR) or n (%)
p-value
Age (y) 9.10 ± 1.41 9.33 ± 1.29 9.38 ± 1.29 0.385† 
Sex 
Male 
Female 
27 (37.0%)
46 (63.0%)
22 (31.0%)
49 (69.0%)
39 (50.0%)
9 (50.0%)
0.051‡ 
Race 
White 
Black 
Others
43 (58.9%)
22 (30.1%)
8 (11.0%)
45 (33.1%)
19 (26.8%)
7 (9.9%)
48 (61.5%)
21 (26.9%)
9 (11.5%)
0.982‡ 
Measures of adiposity 
BMI (kg/m2) 25.23 ± 2.01 29.6 ± 1.36 35.81 ± 3.74 <0.001† 
BMI percentile 97.97 ± 1.63 99.30 ± 0.24 99.67 ± 0.15 <0.001† 
Relative BMI 1.55 ± 0.11 1.8 ± 0.06 2.18 ± 0.22 <0.001† 
Measures of blood pressure
SBP (mmHg) 117.47 ± 8.83 121.96 ± 9.85 121.92 ± 11.74 0.010† 
DBP (mmHg) 66.81 ± 6.31 68.00 ± 6.18 66.74 ± 7.14 0.433† 
Measures of glucose tolerance / insulin resistance
F GLU (mg/dL) 93.08 ± 7.35 92.61 ± 6.70 92.08 ± 7.43 0.691† 
F INS  (u IU/mL) 11.6 (9.75) 15.10 (7.60) 18.11 (12.67) <0.001§ 
2H GLU (mg/dL) 118.16 ± 24.52 120.52 ± 23.60 121.21 ± 23.36 0.717† 
FGIR 7.95 (6.69) 5.91 (2.82) 5.10 (3.54) <0.001§ 
HOMA-IR 2.68 (2.43) 3.27 (1.74) 4.11 (2.89) <0.001§ 
Measures of serum lipids
TG (mg/dL) 88.00 (83.00) 94.00 (84.00) 91.50 (59.00) 0.601§ 
HDL (mg/dL) 42.60 ± 9.89 41.72 ± 9.16 40.88 ± 9.17 0.534† 
CHOL (mg/dL) 165.92 ± 40.27 165.17 ± 26.84 163.03 ± 29.88 0.853† 
Single-factor ANOVA or Kruskal-Wallis tests were conducted to test differences in continuous variables (e.g., age) among rBMI 
categories. Chi-square test was used to examine differences in categorical variable (e.g., race) among rBMI categories.   
† Single-factor ANOVA 
‡ Chi-square test 
§Kruskal-Wallis test
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Table 10 
Metabolic Abnormalities in Overall Sample by rBMI Category 
Characteristics
Overall 
N=222 
n (%)
rBMITertile 1 
N=73 
n (%)
rBMITertile 2 
N=71 
n (%)
rBMITertile 3 
N=78 
n (%)
p-value†
Blood pressure
Pre HTN
S1 HTN
S2 HTN
29 (13.1%)
87 (39.2%)
24 (10.8%)
11 (15.1%)
24 (32.9%)
5 (6.8%)
10 (14.1%)
32 (45.1%)
8 (11.3%)
8 (10.3%)
31 (39.7%)
11 (14.1)
0.380
F GLU ≥ 100 mg/dL 27 (12.2%) 8 (11.0%) 7 (9.9%) 12 (15.4%) 0.546
F INS ≥ 17 u IU/mL 89 (40.1%) 22 (30.1%) 25 (35.2%) 42 (53.8%) 0.007
Impaired GTT:
140-199 mg/dL @ 2h 
26 (11.7%) 5 (6.8%) 11 (15.5%) 10 (12.8%) 0.254
Type 2 DM:
≥ 200 mg/dL@ 2 h
3 (1.4%) 1 (1.4%) 1 (1.4%) 1 (1.3%) 0.998
HDL < 35 mg/dL 44 (19.8%) 12 (16.4%) 14 (19.7%) 18 (23.1%) 0.593
TG > 150 mg/dL 41 (18.5%) 13 (17.8%) 17 (23.9%) 11 (14.1) 0.298
† Chi-square test
Figure 5. Metabolic Abnormalities by rBMI Category
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Table 11 
Demographics and Metabolic Characteristics of Males by rBMI Category 
Characteristics
rBMITertile 1 
N=27 
Mean ± sd, Median 
(IQR) or n (%)
rBMITertile 2 
N=22 
Mean ± sd, Median 
(IQR) or n (%)
rBMITertile 3 
N=39 
Mean ± sd, Median 
(IQR) or n (%)
p-value
Age (yrs) 9.21 ± 1.47 9.61 ± 1.25 9.23 ± 1.38 0.524† 
Race 
White 
Black 
 Others
17 (63.0%)
9 (33.3%)
1 (3.7%)
17 (77.3%)
2 (9.1%)
3 (13.6%)
28 (71.8%)
10 (25.6%)
1 (2.6%)
0.150‡ 
Measures of adiposity 
BMI (kg/m2) 25.58 ± 1.33 29.94 ± 1.29 35.54 ± 4.61 <0.001† 
BMI percentile 98.56 ± 0.77 99.31 ± 0.24 99.63 ± 0.18 <0.001† 
Relative BMI 1.57 ± 0.07 1.82 ± 0.07 2.17 ± 0.28 <0.001† 
Measures of blood pressure
SBP (mmHg) 116.89 ± 8.92 112.09 ± 10.57 121.05 ± 11.61 0.174† 
DBP (mmHg) 67.52 ± 6.85 67.86 ± 5.69 66.33 ± 8.16 0.680† 
Measures of glucose tolerance / insulin resistance
F GLU (mg/dL) 94.22 ± 9.28 94.41 ± 5.44 94.23 ± 7.12 0.995† 
F INS  (u IU/mL ) 10.40 (4.67) 13.40 (6.97) 14.20 (11.80) 0.006§ 
2H GLU (mg/dL) 119.11 ± 17.97 122.91 ± 27.58 120.49 ± 27.26 0.867† 
FGIR 9.41 (4.55) 6.90 (5.29) 6.21 (4.75) 0.005§ 
HOMA-IR 2.37 (1.49) 2.97 (1.62) 3.45 (2.40) 0.007§ 
Measures of serum lipids
TG (mg/dL) 67.00 (86.00) 104.00 (81.25) 72.00 (60.00) 0.278§ 
HDL (mg/dL) 44.89 ± 10.91 43.18 ± 10.80 42.67 ± 9.67 0.685† 
CHOL (mg/dL) 177.41 ± 45.15 167.14 ± 31.03 164.64 ± 25.76 0.314† 
Single-factor ANOVA or Kruskal-Wallis tests were conducted to test differences in continuous variables (e.g., age) 
among rBMI categories. Chi-square test was used to examine differences in categorical variable (e.g., race) among 
rBMI categories. 
† Single-factor ANOVA 
‡ Chi-square test
§Kruskal-Wallis test 
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Table 12
Metabolic Abnormalities in Males by rBMI Category 
Characteristics
Overall 
N=88 
n (%)
rBMITertile 1 
N=27 
n (%)
rBMITertile 2 
N=22 
n (%)
rBMITertile 3 
N=39 
n (%)
p-value†
Blood pressure
Pre HTN
S1 HTN
S2 HTN
9 (10.2%)
34 (38.6%)
10 (11.4%)
4 (14.8%)
8 (29.6%)
2 (7.4%)
2 (9.1%)
11 (50.0%)
3 (13.6%)
3 (7.7%)
15 (38.6%)
10 (11.4%)
0.672
F GLU ≥ 100 mg/dL 17 (19.3%) 4 (14.8%) 3 (13.6%) 10 (25.6%) 0.405
F INS ≥ 17 u IU/mL 22 (25.0%) 3 (11.1%) 4 (18.2%) 15 (38.5%) 0.029
Impaired GTT: 140-199 
mg/dL @ 2h 
12 (13.6%) 2 (7.4%) 6 (27.3%) 4 (10.3%) 0.093
Type 2 DM:
≥ 200 mg/dL @ 2 h
1 (1.1%) 0 (0.0%) 0 (0.0%) 1 (2.6%) -
HDL < 35 mg/dL 13 (14.8%) 2 (7.4%) 4 (18.2%) 7 (17.9%) 0.432
TG > 150 mg/dL 14 (15.9%) 4 (14.8%) 5 (22.7%) 5 (12.8%) 0.587
† Chi-square test
Table 13
Demographics and Metabolic Characteristics of Females by rBMI Category 
Characteristics
rBMITertile 1 
N=46 
Mean ± sd, Median 
(IQR) or n (%)
rBMITertile 2 
N=49 
Mean ± sd, Median (IQR) 
or n (%)
rBMITertile 3 
N=39 
Mean ± sd, Median 
(IQR) or n (%)
p-value
Age (yrs) 9.03 ± 1.39 9.20 ± 1.30 9.53 ± 1.19 0.202† 
Race 
White 
Black 
Others
26 (56.5%)
13 (28.3%)
7 (15.2%)
28 (57.1%)
17 (34.7%)
4 (8.2%)
20 (51.3%)
11 (28.2%)
8 (20.5%)
0.563‡ 
Measures of adiposity 
BMI (kg/m2) 25.02 ± 2.30 29.45 ± 1.38 36.09 ± 2.64 <0.001† 
BMI percentile 97.62 ± 1.89 99.29 ± 0.24 99.70 ± 0.09 <0.001† 
Relative BMI 1.53 ± 0.13 1.80 ± 0.06 2.18 ± 0.14 <0.001† 
Measures of blood pressure
SBP (mmHg) 117.80 ± 8.87 121.90 ± 9.63 122.79 ± 11.96 0.050† 
DBP (mmHg) 66.39 ± 6.02 68.06 ± 6.44 67.15 ± 6.03 0.421† 
Measures of glucose tolerance / insulin resistance
F GLU (mg/dL) 92.41 ± 5.95 91.80 ± 7.10 89.92 ± 6.53 0.202† 
F INS  (u IU/mL) 13.30 (12.41) 16.00 (7.55) 20.80 (11.49) 0.002§ 
2H GLU (mg/dL) 117.61 ± 27.83 119.45 ± 21.81 121.92 ± 19.01 0.698† 
FGIR 6.75 (8.05) 5.61 (2.37) 4.33 (2.87) 0.001§ 
HOMA-IR 3.09 (2.78) 3.64 (1.99) 4.41 (2.70) 0.005§ 
Measures of serum lipids
TG (mg/dL) 91.00 (83.50) 88.00 (87.00) 94.00 (55.00) 0.989§ 
HDL (mg/dL) 41.26 ± 9.09 41.26 ± 9.09 39.10 ± 8.39 0.456† 
CHOL (mg/dL) 159.17 ± 35.94 159.17 ± 35.94 161.41 ± 33.77 0.733† 
Single-factor ANOVA or Kruskal-Wallis tests were conducted to test differences in continuous variables (e.g., age) 
among rBMI categories. Chi-square test was used to examine differences in categorical variable (e.g., race) among 
rBMI categories. † Single-factor ANOVA; ‡ Chi-square test;  § Kruskal-Wallis test 
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Table 14 
Metabolic Abnormalities in Females by rBMI Category 
Characteristics
Overall 
N=134 
n (%)
rBMITertile 1 
N=46 
n (%)
rBMITertile 2 
N=49 
n (%)
rBMITertile 3 
N=39 
n (%)
p-value†
Blood pressure
Pre HTN
S1 HTN
S2 HTN
20 (14.9%)
53 (39.6%)
14 (10.4%)
7 (15.2%)
16 (34.8%)
3 (6.5%)
8 (16.3%)
21 (42.9%)
5 (10.2%)
5 (12.8%)
16 (41.0%)
6 (15.4%)
0.730
F GLU ≥ 100 mg/dL 10 (7.5%) 4 (8.7%) 4 (8.2%) 2 (5.1%) 0.801
F INS ≥ 17 u IU/mL 67 (50.0%) 19 (41.3%) 21 (42.95) 27 (69.0%) 0.017
Impaired GTT: 140-199 
mg/dL @ 2h 
14 (10.4%) 3 (6.5%) 5 (10.2%) 6 (15.4%) 0.411
Type 2 DM:
≥ 200 mg/dL @ 2 h
2 (1.5%) 1 (2.2%) 1 (2.0%) 0 (0.0%) -
HDL < 35 mg/dL 31 (23.1%) 10 (21.7%) 10 (20.4%) 11 (28.2%) 0.664
TG > 150 mg/dL 27 (20.1%) 9 (19.6%) 12 (24.5%) 6 (15.4%) 0.567
† Chi-square test
Demographic Characteristics 
There was no significant difference among rBMI tertiles with regards to age.  The mean ± 
sd ages of subjects were 9.10 ± 1.41 years, 9.33 ± 1.29 years, and 9.38 ± 1.29 years in tertiles 
one, two, and three, respectively (Table 9). When subjects were divided into male and female 
groups, mean ages were not significantly different across tertiles (Tables 11 and 13).  In the 
overall sample, there was no significant difference in sex distribution among rBMI tertiles (Table 
9). Similarly, there was no significant difference in racial distribution among rBMI tertiles, both 
when the population was considered as a whole, and when it was divided by sex (Tables 9, 11, 
and 13). 
Blood Pressure
There were significant differences in systolic blood pressure among rBMI tertiles.  In 
rBMI tertile one, mean systolic blood pressure was 117.47 ± 8.83 mmHg; in rBMI tertile two, 
mean systolic blood pressure was 121.96 ± 9.85 mmHg; in rBMI tertile three, mean systolic 
blood pressure was 121.92 ± 11.74 mmHg. Single-factor ANOVA suggests that these means are 
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significantly different at p=0.01(Table 9).  When subjects were divided by sex, there was no 
significant difference in systolic blood pressure among rBMI tertiles in males (Table 11).  In 
females, however, differences in systolic blood pressure were significant at p=0.05 (Table 13).  
There were no significant differences in mean diastolic blood pressure among rBMI tertiles, both 
when the population was considered as a whole, and when it was divided by sex (Tables 9, 11, 
and 13). 
When age, height, and sex-specific cutoffs for blood pressure were applied, there was no 
significant difference in the proportion of subjects with prehypertension, stage 1 hypertension, 
and stage 2 hypertension among rBMI tertiles (Table 10).  When subjects were divided into male 
and female groups, there was still no significant difference in the frequency of prehypertension, 
stage 1 hypertension, and stage 2 hypertension among the rBMI tertiles (Tables 12 and 14).   
Glucose Levels
Overall, there was no significant difference in fasting glucose levels among the rBMI 
tertiles (Table 9). When subjects were divided into male and female groups, there was still no 
significant difference in mean fasting glucose among rBMI tertiles (Tables 11 and 13).  When 
the American Diabetes Association cutoff for impaired fasting glucose was applied, there was no 
significant difference in prevalence among rBMI tertiles for the whole population, for males, or 
for females (Tables 10, 12, and 14). 
There was no significant difference in mean two hour glucose on glucose tolerance test 
among rBMI tertiles for the study population as a whole, for males, or for females (Tables 9, 11, 
and 13). Similarly, there were no significant differences in prevalence of impaired glucose 
tolerance or type 2 diabetes among rBMI tertiles (Tables 10, 12, and 14). 
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Fasting Insulin and Insulin Sensitivity Indices
There were highly significant differences in insulin levels among rBMI tertiles.  Overall, 
the median fasting insulin was 11.60 u IU/mL in tertile one, 15.10 u IU/mL in tertile two, and 
18.11 u IU/mLin tertile three; these medians are significantly different at p<0.001 using the 
Kruskal-Wallis test (Table 9).  Differences in median fasting insulin among rBMI tertiles 
remained significant when the population was split by sex, with p=0.006 for males and p=0.002 
for females (Tables 11 and 13). 
Similarly, there was a significant difference in the proportion of subjects with abnormal 
fasting insulin of greater than or equal to 17 u IU/ml among rBMI tertiles (p=0.007).  In tertile 
one, 30.1% of subjects had abnormal fasting insulin; in tertile two, 35.2% of subjects had 
abnormal fasting insulin; in tertile three, 53.8% of subjects had abnormal fasting insulin (Table 
10). Differences in the proportion of subjects with abnormal fasting insulin among rBMI tertiles 
remained significant when the population was split by sex (Tables 12 and 14).   
As is to be expected considering differences in insulin levels, there were significant 
differences in FGIR and HOMA-IR among rBMI tertiles.  The median FGIR in tertile one was 
7.95, the median FGIR in tertile two was 5.91, and the median FGIR in tertile three was 5.10; 
these values are significantly different (p<0.001).  Similarly, the median HOMA-IR value was 
2.68 in tertile one, 3.27 in tertile two, and 4.11 in tertile three (p<0.001) (Table 9).  Differences 
in median FGIR and HOMA-IR among rBMI tertiles remained significant when the population 
was split by sex (Tables 11 and 13). 
Serum Lipids
There were no significant differences in median triglyceride levels, mean HDL levels, or 
mean total cholesterol levels among rBMI tertiles; this was true for the entire study population 
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and when the population was separated by sex (Tables 9, 11, and 13).  Similarly, when HDL and 
triglyceride levels were considered using the American Diabetes Association’s cutoffs, there 
were no significant differences in prevalence of low HDL or high triglycerides among rBMI 
tertiles (Tables 10, 12, and 14). 
Metabolic Syndrome 
Table 15 
Distribution of Metabolic Syndrome Components in Overall Sample, and rBMI Category 
Number of 
Components† 
Overall 
N=222 
n (%)
rBMITertile 1 
N=73 
n (%)
rBMITertile 2 
N=71 
n (%) 
rBMITertile 3 
N=78 
n (%)
p-value‡ 
1 49 (22.1%) 18 (24.7%) 13 (18.3%) 18 (23.1%) 
0.217 
2 111 (50.0%) 42 (57.5%) 34 (47.9%) 35 (44.9%) 
3 46 (20.7%) 11 (15.1%) 15 (21.1%) 20 (25.6%) 
4 13 (5.9%) 1 (1.4%) 7 (9.9%) 5 (6.4%) 
5 3 (1.4%) 1 (1.4%) 2 (2.8%) 0 (0.0%) 
†Components of metabolic syndrome include BMI≥85th percentile, HDL<35, TG>150, 2H glu≥140, and 

prehypertension/hypertension

‡ Chi-Square test
 
Note: Everyone is qualified for at least one abnormality based on BMI criteria for inclusion in the study. 

Figure 6. Distribution of Metabolic Syndrome Components in Overall Sample, and by rBMI 
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Table 16 
Prevalence of Metabolic Syndrome by rBMI Category
Metabolic syndrome† Overall 
n (%)
rBMITertile 1 
n (%)
rBMITertile 2 
n (%)
rBMITertile 3 
n (%)
p-value‡ 
Overall Sample N=222 N=73 N=71 N=78
62 (27.9%) 13 (17.8%) 24 (33.8%) 25 (32.1%) 0.061 
Males N=88 N=27 N=22 N=39 
20 (22.7%) 3 (11.1%) 8 (36.4%) 9 (23.1%) 0.110 
Females N=134 N=46 N=49 N=39 
42 (31.3%) 10 (21.7%) 16 (32.7%) 16 (41.0%) 0.156 
Metabolic syndrome is defined as BMI≥85th percentile plus 2 or more of the following variables:  1) HDL<35, 2)
TG>150, 3) 2H glu≥140, and 4) prehypertension/hypertension
‡Chi-square test
 
Note: Everyone is qualified for at least one abnormality based on BMI criteria. 

Metabolic abnormalities were clustered into the metabolic syndrome, defined as BMI 
greater than or equal to the 85th percentile, plus two or more of the following variables:  HDL 
less than 35 mg/dL, triglycerides greater than 150 mg/dL, two hour glucose of 140 mg/dL or 
greater, and prehypertension/hypertension.  Using this definition, 17.8% of subjects in rBMI 
tertile one, 33.8% in rBMI tertile two, and 32.1% in rBMI tertile three had metabolic syndrome.  
These proportions were not significantly different when tested using chi-square analysis (Table 
16). 
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Discussion
Prevalence and Determinants of Metabolic Syndrome among Overweight and Obese 
Children 
The prevalence of metabolic syndrome among obese children and adolescents has varied 
greatly among studies, likely due to differences in study populations and the definitions used for 
metabolic syndrome.  The overall prevalence of metabolic syndrome in this study was 27.9%.  
This is slightly higher than a prevalence of 19.1% among obese children in Pedrosa and 
colleagues’ (2010) examination of metabolic syndrome in 7-9 year old Portuguese 
schoolchildren. This may be due to dissimilarity in characteristics of the population from which 
subjects were drawn; our study is based on patients who were referred to a hospital-based clinic, 
while Pedrosa’s study recruited subjects from public schools.   
Conversely, prevalence of metabolic syndrome found in this study population was lower 
than in many other studies.  Sen et al.’s 2008 study, which examined obese children aged 2-19 
years referred to a university clinic, found a prevalence of 41.8%.  Additionally, Weiss’s 2004 
study of obese children aged 2-19 years found a prevalence of 38.7% to 49.7 % depending on 
severity of obesity. De Ferranti and colleagues (2004), who examined adolescents aged 12 to 19 
years, found a prevalence of metabolic syndrome of 31.2% among overweight and obese 
children. It is possible that the prevalence in this study is lower because the target age range in 
this study is lower (6-10 years) than in aforementioned studies, and multiple studies have found 
that older children are at higher risk for metabolic syndrome than younger children (Lambert et 
al., 2008, Sen et al., 2008). In this study, for example, mean age of participants was 9.27 years, 
while the Sen and Weiss studies both had subjects with a mean age of 12.1 years.  Similarly, this 
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study examined children aged 6 to 10 years, while DeFerranti examined adolescents aged 12 to 
19 years. 
In contrast to studies by Calcaterra and colleagues (2008) and Sen and colleagues (2008), 
this study did not find any significant difference in prevalence of metabolic syndrome based on 
degree of obesity. Similarly, Calcaterra and Sen found significant differences in the number of 
metabolic abnormalities per individual based on severity of obesity, while this study did not.  In 
this study, there was no significant difference in prevalence of metabolic syndrome between boys 
and girls, which is consistent with several other studies which examined children under the age 
of 10 years (Calcaterra et al., 2008; Pedrosa et al., 2010; Rinaldi et al., 2010).   
Prevalence of Individual Metabolic Abnormalities among Overweight and Obese Children 
Hypertension 
Mean systolic blood pressure of 120.47 mmHg in this study was similar to mean systolic 
blood pressure of overweight and obese subjects in several other studies.  For example, Sen and 
colleagues (2008) found a mean of 115.8 mmHg, Calcaterra and colleagues (2008) found a mean 
of 116.5 mmHg, and Weiss and colleagues (2004) found a mean of 121.9 mmHg.  In this study, 
mean systolic blood pressure was significantly different among rBMItertiles.  In other studies, 
blood pressure increased incrementally with increasing BMI z-score (Weiss et al., 2004; 
Calcaterra et al., 2008). While in this study, mean systolic blood pressure varied among rBMI 
tertiles, prevalence of abnormal blood pressure did not vary significantly with degree of obesity.  
This is in contrast to Sen and colleagues’ 2008 study, which found that the prevalence of 
hypertension was significantly different (p=0.001) among groups of children stratified by BMI z-
score. 
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The prevalence of abnormal blood pressure among subjects in this study was alarmingly 
high. When age, height, and sex-specific cutoffs for hypertension were applied, 13.1% of 
subjects had blood pressure readings consistent with pre-hypertension, 39.2% had readings 
consistent with stage 1 hypertension, and 10.8% had readings consistent with stage 2 
hypertension. This leaves only 36.9% of subjects who were normotensive.  Pedrosa and 
colleagues (2010) had similar results, finding prehypertension or hypertension in almost 70% of 
overweight and obese children aged 7-9 years. Other studies had a much lower prevalence of 
abnormal blood pressure levels.  For example, Cook, Weitzman, Auinger, Nguyen, and Dietz’s 
2003 study of adolescents aged 12 to 19 found that only 8.6% of overweight and 11.2% of obese 
subjects had prehypertension or hypertension.  Similarly, Lambert and colleagues (2008) found 
that 28.8% of overweight and 39.6% of obese subjects had prehypertension or hypertension.   
The high rate of hypertension in this study may be partly due to methodological error; 
both Cook and Lambert took the mean of multiple blood pressure readings, while most subjects 
in this study had their blood pressure measured only one time.  Additionally, elevated blood 
pressure may be in part to white coat hypertension, which is when patients exhibit elevated blood 
pressure in clinical settings but not in other settings.  Studies of white coat hypertension in 
children have reported prevalence of 44-88%, depending on the thresholds used for hypertension 
(Sorof, 2000). While white coat hypertension may be a contributor to the high prevalence of 
hypertension in this study, it does not explain the significant difference in systolic blood pressure 
among rBMItertiles.   
Impaired Fasting Glucose, Impaired Glucose Tolerance, and Type 2 DM 
In this study, 12.2% of subjects had impaired fasting glucose, defined as fasting glucose 
greater than or equal to 100 mg/dL.  Mean fasting glucose levels and the prevalence of impaired 
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fasting glucose were significantly higher in males than in females in this study; similar findings 
were apparent in other studies (Duncan et al., 2004; Lambert et al., 2008).  In this study, 11.7% 
of subjects had impaired glucose tolerance, and 1.4% of subjects had type 2 diabetes.  This is 
quite different from Sen and colleagues’ 2008 study, which found a 6.0% prevalence of impaired 
glucose tolerance, and 2.6% prevalence of type 2 diabetes in obese children aged 2-19 years.   
There were no significant differences in mean fasting glucose or mean 2 hour glucose 
among rBMI tertiles in this study.  This is in contrast to Calcaterra and colleagues’ study (2008) 
which found significant differences in mean fasting glucose and mean 2 hour glucose among 
overweight, moderately obese, and severely obese subjects.  In this study, there were also no 
significant differences in the proportion of subjects who had impaired fasting glucose or 
impaired glucose tolerance among rBMI tertiles.  Weiss and colleagues (2004), however, found 
significant differences in the prevalence of impaired glucose tolerance among subjects who were 
overweight, moderately obese, and severely obese.   
Fasting Insulin and Insulin Sensitivity Indices
In this study, median fasting insulin for the entire population was 14.90 u IU/mL; in 
Calcaterra and colleagues’ 2008 study and in Sen and colleagues’ 2008 study, mean fasting 
insulin levels were 13.6 u IU/mL and 16.4 u IU/mL, respectively.  Fasting insulin in this study 
was significantly different among rBMI tertiles, with insulin levels rising with increasing 
severity of obesity; the same trend was observed in the Sen and Calcaterra studies.   
Overall, 40.1% of subjects had elevated fasting insulin using the cutoff of insulin greater
than or equal to 17 u IU/mL. The true percentage of subjects with fasting hyperinsulinemia was 
likely much higher because the fasting insulin cutoff for prepubertal children is greater than or 
equal to 13 u IU/mL (Jean et al., 2009; Arslanian, Suprasongsin, & Janosky, 1997).  Because 
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pubertal staging was not available for study subjects, a conservative choice was made to use the 
17 u IU/mL cutoff, but it is likely that many of the subjects, particularly male, were still 
prepubertal. The proportion of subjects with abnormal fasting insulin was significantly different 
among rBMI tertiles, with the prevalence of abnormal fasting insulin rising with increasing 
severity of obesity; this trend was seen in several other studies (Weiss et al., 2004; Lambert et 
al., 2008). 
As is to be expected considering differences in insulin levels, there was a significant 
difference in FGIR among rBMI tertiles.  FGIR is inversely related to insulin resistance, with 
FGIR decreasing as insulin resistance increases.  There was also a significant difference in 
HOMA-IR among rBMI tertiles. HOMA-IR increases as insulin resistance increases.  These 
results are consistent with the literature; in a 2002 study examining the relationship between 
adiposity and insulin resistance, body fat accounted for 55% of the variance in insulin sensitivity 
after adjusting for age, gender, race, and pubertal stage (Caprio, 2002).  In another study by 
Velasquez-Meiyer and colleagues (2008), two different indices of insulin sensitivity decreased 
significantly as the severity of overweight increased. 
This study suggests that the prevalence of insulin resistance is higher in females than in 
males.  Median fasting insulin was significantly higher for females than for males, and the 
proportion of females with elevated fasting insulin was twice that of males.  Similarly, median 
FGIR was lower for females than for males, and median HOMA-IR was higher for females than 
males.  This is consistent with the literature. In one study of healthy five year old children, girls 
were 33% more insulin resistant than boys after adjusting for body fat and physical activity 
(Murphy et al., 2004). Several studies suggest that the relationship between gender and insulin 
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resistance continues into adolescence, with girls having a higher prevalence of insulin resistance 
independent of pubertal stage and adiposity (Travers, Jeffers, Bloch, Hill, & Eckel, 1995).   
Dyslipidemia
In this study, the median triglyceride level of subjects was 90.50 mg/dL, and 18.5% of 
subjects had abnormal triglyceride levels of greater than 150 mg/dL.  This is similar to a 2008 
study by Lambert and colleagues in which 17.5% of subjects had triglycerides greater than 150 
mg/dL. Several studies reviewed used a less stringent definition of elevated triglycerides of
greater than or equal to 110 mg/dL; these studies found a slightly higher prevalence.  For 
example, Cook and colleagues (2003) found a prevalence of 23.4% among obese adolescents, 
and Duncan, Li, and Zhou (2004) found a prevalence of 23.2% among obese adolescents.   
This study found no significant differences in median triglyceride levels or the prevalence 
of elevated triglycerides between the sexes; Pedrosa et al. (2010) had similar findings in a study 
of 7-9 year old children. In contrast, a study by Lambert and colleagues (2008) found 
significantly higher triglyceride levels in overweight and obese females than in overweight and 
obese males.  Additionally, this study found no significant differences in median triglyceride 
levels or the prevalence of elevated triglycerides among rBMItertiles; however, several studies 
found that mean triglyceride levels were significantly higher in more obese children (Weiss et 
al., 2004; Calcaterra et al., 2008). 
In this study, 19.8% of subjects had abnormal HDL levels of less than 35 mg/dL, which 
is lower than in several other studies. Lambert and colleagues (2008) found a prevalence of 
25.7% using the same cutoff as was used in this study.  Duncan and colleagues (2004) and Cook 
and colleagues (2003) found prevalences of 23.4% and 23.3%, respectively, using a less 
stringent cutoff of less than or equal to 40 mg/dL.  This study found no significant differences in 
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mean HDL levels or the prevalence of low HDL among rBMItertiles; however, several studies 
found that mean HDL levels were lower higher in more obese children (Weiss et al., 2004; 
Calcaterra et al., 2008). 
Limitations
This study has several limitations.  Because subjects were selected from a referral-based 
clinic, and because only children with an extensive biochemical workup could be included in the 
study, this study may not accurately describe the prevalence of metabolic abnormalities in obese 
children.  Additionally, because physicians in the clinic chose what biochemical tests to perform
based on physical examination, it is possible that subjects with the appropriate labs to be 
included in the study all had similar risk profiles; this may explain why there was no apparent 
effect of relative obesity on prevalence of metabolic abnormalities.   
This study, like all studies which examine the metabolic syndrome in children, is limited 
by the lack of a consistent, accepted definition for the condition in pediatrics.  This lack of 
standardized parameters makes it difficult to compare the prevalence of metabolic syndrome 
across studies. In addition, this study fails to consider factors such as birth history, family 
history, lifestyle, and pubertal stage, which may affect the development of metabolic 
abnormalities.  Because of its cross-sectional design, this study does not allow for causal 
inference; instead, it simply describes a correlation between relative obesity and prevalence of 
metabolic risk factors.  Finally, each risk factor with the exception of obesity was defined by a 
singular cutoff point, which may not thoroughly describe the continuum of risk.    
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Implications and Recommendations 
The Need for Aggressive Screening 
Current recommendations for physical and biochemical assessment of overweight and 
obese children are outlined in the Expert Committee Recommendations Regarding the
Prevention, Assessment, and Treatment of Child and Adolescent Overweight and Obesity 
(Barlow & The Expert Committee, 2007).  The results of this study suggest that the Expert 
Committee guidelines are insufficient for school-age children; more aggressive screening of 
overweight and obese children aged 6 to 10 years is warranted because the prevalence of such 
abnormalities is significant in this population.   
The 63.1% prevalence of pre-hypertension and hypertension in this study population 
reinforces the Expert Committee recommendation to check blood pressure at all health 
supervision visits. However, most of the Expert Committee’s recommendations are not 
aggressive enough.  The Expert Committee’s current recommendation is to obtain a fasting lipid 
profile in all overweight and obese children over the age of 10 years.  Almost 20% of this study’s 
6-10 year-old subjects had elevated triglycerides, and almost 20% had low HDL, suggesting that 
children under the age of 10 years are at risk of dyslipidemia and should have a fasting lipid 
panel drawn upon initial assessment.  Similarly, the Expert Committee recommends checking 
fasting glucose in all obese children over the age of 10 years.  This recommendation may be 
insufficient as 12.2% of the 6-10 year old children in this study had impaired fasting glucose.   
The Expert Committee does not recommend oral glucose tolerance tests or fasting insulin 
tests in overweight and obese children; however, this study suggests that both tests may be useful 
assessment tools in this population.  Overall, 13% of children in this study had abnormal blood 
glucose levels at the 2 hour point on OGTT, and a substantial proportion of those children had 
 
 
 
53 
normal fasting glucose levels.  Additionally, 40.1% of study subjects had elevated fasting insulin 
levels, which never would have been found had the Expert Committee’s recommendations been 
followed. Elevated fasting insulin levels suggest insulin resistance, which has been implicated in 
the pathophysiology of type 2 diabetes, non-alcoholic fatty liver disease, and cardiovascular 
disease (Steinberger et al., 2009). 
The Importance of Relative Obesity in School-Age Children 
Multiple studies have suggested that prevalence of metabolic syndrome, prevalence of 
individual metabolic abnormalities, and the number of abnormalities per individual increase with 
higher levels of adiposity (Weiss et al., 2004; Lambert et al., 2008, Calcaterra et al., 2008).  In 
this study, however, the only differences noted among rBMItertiles were in systolic blood 
pressure, fasting insulin, and insulin sensitivity indices.  This may be explained by age 
differences in study populations, because the participants in this study were much younger than 
the populations of the Weiss, Lambert, and Calcaterra studies, which included adolescents up to 
the ages of 16 to 20 years. The one study which examined only children aged 7 to 9 years had 
similar findings to this study, with only systolic blood pressure showing a significant difference 
among children of different degrees of overweight/obesity (Pedrosa et al., 2010).  As a result, we 
may hypothesize that degree of obesity has less of an effect on development of metabolic 
abnormalities among younger children than among older children and adolescents.  
The Need for Aggressive Intervention
Metabolic risk factors in early in childhood may lead to chronic diseases later in 
childhood, including type 2 diabetes, non-alcoholic fatty liver disease, and early signs of 
cardiovascular disease such as left ventricular hypertrophy and thickening of the artery walls 
(Calcaterra et al., 2008; Kapiotis et al., 2006; Chinali et al., 2008).  Additionally, childhood 
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metabolic syndrome tracks into adulthood and is a risk factor for adult disease (Magnussen et al., 
2010; Morrison et al., 2007). In fact, development of risk factors early in life may result in 
earlier onset of cardiovascular disease and poorer outcomes due to longer duration of exposure 
(Halpern et al., 2010). 
This study suggests that 6-10 year old obese children who are referred for treatment are a 
population at high risk of morbidity, with 27.9% of subjects in this study having the metabolic 
syndrome phenotype.  Fortunately, aggressive intervention including dietary counseling, 
structured physical activity, behavioral/family counseling, and even medication or bariatric 
surgery, may reduce the risk of illness in obese children.  Childhood is an optimal time to shape 
healthy behaviors; additionally, the potential damage to the cardiovascular system in childhood 
is reversible.  When at-risk children are identified early and treated aggressively, the threat of 
future disease can be mitigated (Battista et al., 2009).   
Areas for Further Study
There are a number of additional analyses which could be performed on the dataset from
this study. This study primarily compared continuous or categorical metabolic parameters to 
categories of relative obesity; it would be interesting to see if there are significant correlations 
between continuous metabolic parameters and rBMI as a continuous variable.  In addition, one 
could quantify a relationship between categorical metabolic parameters and rBMI as a 
continuous variable using logistic regression.  Finally, it would be very interesting to compare 
average values of metabolic parameters between subjects with and without the metabolic 
syndrome.  This may provide some insights into which metabolic parameters, besides obesity, 
are major contributing factors to the metabolic syndrome in obese young children.   
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Conclusion
The presence of metabolic abnormalities in children greatly increases the risk for medical 
problems such as type 2 diabetes and cardiovascular disease.  The results of this study suggest 
that 6-10 year old obese children who are referred for treatment are a population at high risk of 
morbidity; 77.9% of subjects had at least one metabolic abnormality in addition to obesity, and 
27.9% of subjects in this study had metabolic syndrome.  This study also suggests that there is a 
high risk of elevated systolic blood pressure and elevated fasting insulin in obese children aged 6 
to 10 years; this risk increases as degree of obesity increases.  While impaired fasting glucose, 
impaired glucose tolerance, and dyslipidemia are quite prevalent in this study population, the risk 
of these abnormalities does not appear to increase as the severity of obesity increases.  The 
prevalence of insulin resistance may be higher in females than in males, and impaired fasting 
glucose may be higher in males than in females.   
This study also suggests that current recommendations for screening of metabolic 
abnormalities in obese school-age children are not sufficiently aggressive.  The International 
Diabetes Federation’s definition of the metabolic syndrome does not include children under the 
age of 10, and the Expert Committee does not recommend any biochemical assessment for 
children younger than 10 years.  The prevalence of impaired glucose metabolism, insulin 
resistance, and dyslipidemia, however, is significant in this population, and screening for these 
abnormalities in children under the age of 10 is warranted.   
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Appendix C: Public Health Competencies Met 
The following Tier One Public Health Core Competencies were achieved during completion of 
this Culminating Experience project: 
Analytical/Assessment Skills
 Identifies the health status of populations and their related determinants of health and 
illness.
	 Describes the characteristics of a population-based health problem.
	 Uses methods and instruments for collecting valid and reliable quantitative and 
qualitative data. 
	 Recognizes the integrity and comparability of data. 
	 Identifies gaps in data sources. 
	 Adheres to ethical principles in the collection, maintenance, use, and dissemination of 
data and information.   
	 Describes the public health applications of quantitative and qualitative data. 
	 Uses information technology to collect, store, and retrieve data.   
Communication Skills
 Communicates in writing and orally, in person and through electronic means, with 
linguistic and cultural proficiency.  
	 Conveys public health information using a variety of approaches.   
	 Participates in the development of demographic, statistical, programmatic, and scientific 
presentations. 
Community Dimensions of Practice Skills 
	 Recognizes community linkages and relationships among multiple factors (or 

determinants) affecting health.   

Public Health Sciences Skills
	 Describes the scientific evidence related to a public health issue, concern, or intervention.   
	 Retrieves scientific evidence from a variety of text and electronic sources.   
	 Discusses limitations of research findings.   
	 Partners with other public health professionals in building the scientific base of public 
health. 
